JavaScript is disabled for your browser. Some features of this site may not work without it.
Система будет остановлена для регулярного обслуживания. Пожалуйста, сохраните рабочие данные и выйдите из системы.
Статистика
Жалпы қатысу саны
| Көру | |
|---|---|
| CAPIVASERTIB RESTRICTS SARS-COV-2 CELLULAR ENTRY: A POTENTIAL CLINICAL APPLICATION FOR COVID-19 | 84 |
Бір айдағы саны
| January 2024 | February 2024 | March 2024 | April 2024 | May 2024 | June 2024 | July 2024 | |
|---|---|---|---|---|---|---|---|
| CAPIVASERTIB RESTRICTS SARS-COV-2 CELLULAR ENTRY: A POTENTIAL CLINICAL APPLICATION FOR COVID-19 | 3 | 3 | 5 | 8 | 0 | 3 | 3 |
Файлдарға жүгіну
| Көру | |
|---|---|
| Capivasertib restricts SARS-CoV-2.pdf | 23 |
елдер бойынша
| Көру | |
|---|---|
| United States | 50 |
| Russia | 10 |
| China | 7 |
| Romania | 6 |
| Argentina | 1 |
| Australia | 1 |
| Iran | 1 |
| Sweden | 1 |
| Turkey | 1 |
қалалар бойынша
| Көру | |
|---|---|
| Oakland | 16 |
| Louisville | 13 |
| Moscow | 9 |
| Brasov | 6 |
| Shanghai | 6 |
| Menlo Park | 3 |
| Andover | 2 |
| Ann Arbor | 2 |
| Boardman | 2 |
| Des Moines | 2 |
Ұсыну нұсқаулығы